A COST ANALYSIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES USING CLOPIDOGREL IN ADDITION TO ASPIRIN IN A HONG KONG PUBLIC HOSPITAL

Author(s)

Lee VW1, Chan WK2, Lau WH1, Lee KK1 , 1The Chinese University of Hong Kong, Shatin, Hong Kong, China; 2United Christian Hosptial, Kwun Tong, Hong Kong, China

OBJECTIVE: Results from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study showed that clopidogrel plus aspirin, comparing to aspirin alone, reduced the cardiovascular events (death, myocardial infarction, and stroke) in patients with acute coronary syndromes (ACS). Yet the acquisition cost of clopidogrel is much higher. It would therefore be worthwhile to compare the long term cost impact of these 2 regimens. METHODS: Until recently, only very few patients with ACS received a clopidogrel-aspirin combination therapy in Hong Kong. Therefore a hypothetical cohort was formed and compared to a real group of patients treated with aspirin alone. For the aspirin group, medical history was reviewed and cardiovascular and gastrointestinal events occurring in a period of 12 months after initiation of therapy were recorded. The target cost items included hospitalisation, emergency room visits, outpatient clinic visits, related medications, diagnostic tests, procedures and surgery. For the hypothetical cohort, the probabilities/relative risks for clinical events were adopted from the CURE study. The unit cost of drugs and other resource items were based on the Hong Kong Hospital Authority drug acquisition cost 2001 and Hong Kong Government Gazette 2003 respectively. The perspective of the study was that of a public health organisation. RESULTS: Fifty-four consecutive patients with ACS receiving aspirin therapy were identified over the period of January 1, 2001 to December 31, 2001 from a major public hospital in Hong Kong and studied. The average cost of management per patient over the 10-month period of this group was HKD85,324 (USD$10,940, HKD7.8 = USD$1). Hospitalisation represented the major cost item (64.6%), followed by cost of investigational tests (14.5%) and procedural cost (11.6%). The average cost per patient in the hypothetical cohort was HKD83,903 (USD$10,757). CONCLUSION: According to our analytical model, the overall cost impact between clopidogrel plus aspirin vs aspirin alone in the 2 groups of patients was similar.

Conference/Value in Health Info

2003-11, ISPOR Europe 2003, Barcelona, Spain

Value in Health, Vol. 6, No. 6 (November/December 2003)

Code

PCV41

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Cardiovascular Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×